KRAS Inhibitors Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines

The Key KRAS Inhibitors Companies in the market include - Amgen, Mirati Therapeutics, Novartis, Roche/Genentech, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines, and others.

DelveInsight's "KRAS Inhibitors Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the KRAS Inhibitors, historical and forecasted epidemiology as well as the KRAS Inhibitors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the KRAS Inhibitors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; KRAS Inhibitors Market Forecast [https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the KRAS Inhibitors Market Report:

*
The KRAS Inhibitors market size was valued ~USD 500 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In January 2025, Quanta Therapeutics, a privately held clinical-stage biopharmaceutical company at the forefront of developing innovative oral therapies for RAS-driven cancers, announced advancements in its pipeline of KRAS-directed drug candidates. This includes the clearance of a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application for QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor, which allows the initiation of a Phase 1 clinical trial.

*
In June 2024, Quanta Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing innovative oral treatments for RAS-driven cancers, announced the progress of two clinical trials from its pipeline of KRAS-directed drug candidates. The first patient has been dosed in the monotherapy phase of a Phase 1 trial evaluating QTX3046, a KRASG12D-selective inhibitor. Additionally, patient dosing has commenced in the combination phase of the ongoing Phase 1 trial assessing QTX3034, a multi-KRAS inhibitor that preferentially targets G12D, in combination with cetuximab. Both trials are enrolling patients with KRASG12D-mutated advanced solid tumors.

*
In February 2024, Bristol Myers Squibb reported that the US FDA has granted priority review status to the supplemental New Drug Application (sNDA) for KRAZATI in combination with cetuximab for the treatment of KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024.

*
In January 2024, The European Commission provided conditional approval for KRAZATI to treat advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation, specifically for patients who have experienced disease progression after receiving at least one previous systemic therapy.

*
In 2023, the total number of KRAS-mutated cases in the 7MM exceeded approximately 490,000 and is expected to rise during the forecast period.

*
Among the chosen cancer types, the highest number of KRAS mutant cases is observed in colorectal cancer, followed by pancreatic cancer and non-small cell lung cancer (NSCLC). In the United States, there were approximately 151,000 cases of KRAS mutant colorectal cancer in 2023.

*
The most common KRAS variant detected in non-small cell lung cancer (NSCLC) is G12C, while G12D is the predominant KRAS variation in colorectal cancer (CRC) and pancreatic cancer. In the United States, KRASG12C is found in approximately 37% of NSCLC cases. The highest prevalence of KRASG12D is observed in pancreatic cancer at around 42%, followed by CRC at about 30%.

*
Key KRAS Inhibitors Companies: Amgen, Mirati Therapeutics, Novartis, Roche/Genentech, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines, and others

*
Key KRAS Inhibitors Therapies: LUMAKRAS/LUMYKRAS (sotorasib), KRAZATI (adagrasib), JDQ443, Divarasib, JDQ443, Avutometinib, BI 1701963, GDC-6036, LY353798, RMC-4630, and others

*
The KRAS Inhibitors market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage KRAS Inhibitors pipeline products will significantly revolutionize the KRAS Inhibitors market dynamics.

KRAS Inhibitors Overview

KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of mutated KRAS proteins, which are involved in cell growth and division. KRAS mutations are common in several cancers, including lung, colorectal, and pancreatic cancers, and are associated with aggressive tumor growth and poor prognosis. By specifically targeting mutant KRAS, such as KRAS G12C, these inhibitors disrupt the cancer-promoting signaling pathways, leading to reduced tumor growth. Approved KRAS inhibitors, like sotorasib (Lumakras) and adagrasib (Krazati), represent significant advancements in precision oncology, offering new treatment options for patients with KRAS-driven cancers.

Get a Free sample for the KRAS Inhibitors Market Report:

https://www.delveinsight.com/report-store/kras-inhibitors-market [https://www.delveinsight.com/report-store/kras-inhibitors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

KRAS Inhibitors Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

KRAS Inhibitors Epidemiology Segmentation:

The KRAS Inhibitors market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of KRAS Inhibitors

*
Prevalent Cases of KRAS Inhibitors by severity

*
Gender-specific Prevalence of KRAS Inhibitors

*
Diagnosed Cases of Episodic and Chronic KRAS Inhibitors

Download the report to understand which factors are driving KRAS Inhibitors epidemiology trends @ KRAS Inhibitors Epidemiology Forecast [https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

KRAS Inhibitors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the KRAS Inhibitors market or expected to get launched during the study period. The analysis covers KRAS Inhibitors market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the KRAS Inhibitors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

KRAS Inhibitors Therapies and Key Companies

*
LUMAKRAS/LUMYKRAS (sotorasib): Amgen

*
KRAZATI (adagrasib): Mirati Therapeutics

*
JDQ443: Novartis

*
Divarasib: Roche/Genentech

*
JDQ443: Novartis

*
Avutometinib: Verastem Oncology

*
BI 1701963: Boehringer Ingelheim

*
GDC-6036: Roche

*
LY353798: Eli Lilly

*
RMC-4630: Revolution Medicines

Discover more about therapies set to grab major KRAS Inhibitors market share @ KRAS Inhibitors Treatment Market [https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

KRAS Inhibitors Market Strengths

*
Combining KRAS-targeted therapies with other treatment modalities, such as immunotherapies or traditional chemotherapy, holds promise for improving treatment outcomes. The potential for combination therapies creates additional market opportunities and enhances the overall market strength of KRAS mutations.

KRAS Inhibitors Market Opportunities

*
To enhance the effectiveness of KRASG12C inhibitors in NSCLC, it is crucial to integrate them into the first-line standard of care(SOC). Nevertheless, the currently available agents have encountered difficulties due to toxic side effects when combined with anti-PD-(L)1 therapy.

Scope of the KRAS Inhibitors Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key KRAS Inhibitors Companies: Amgen, Mirati Therapeutics, Novartis, Roche/Genentech, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines, and others

*
Key KRAS Inhibitors Therapies: LUMAKRAS/LUMYKRAS (sotorasib), KRAZATI (adagrasib), JDQ443, Divarasib, JDQ443, Avutometinib, BI 1701963, GDC-6036, LY353798, RMC-4630, and others

*
KRAS Inhibitors Therapeutic Assessment: KRAS Inhibitors current marketed and KRAS Inhibitors emerging therapies

*
KRAS Inhibitors Market Dynamics: KRAS Inhibitors market drivers and KRAS Inhibitors market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
KRAS Inhibitors Unmet Needs, KOL's views, Analyst's views, KRAS Inhibitors Market Access and Reimbursement

To know more about KRAS Inhibitors companies working in the treatment market, visit @ KRAS Inhibitors Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. KRAS Inhibitors Market Report Introduction

2. Executive Summary for KRAS Inhibitors

3. SWOT analysis of KRAS Inhibitors

4. KRAS Inhibitors Patient Share (%) Overview at a Glance

5. KRAS Inhibitors Market Overview at a Glance

6. KRAS Inhibitors Disease Background and Overview

7. KRAS Inhibitors Epidemiology and Patient Population

8. Country-Specific Patient Population of KRAS Inhibitors

9. KRAS Inhibitors Current Treatment and Medical Practices

10. KRAS Inhibitors Unmet Needs

11. KRAS Inhibitors Emerging Therapies

12. KRAS Inhibitors Market Outlook

13. Country-Wise KRAS Inhibitors Market Analysis (2020-2034)

14. KRAS Inhibitors Market Access and Reimbursement of Therapies

15. KRAS Inhibitors Market Drivers

16. KRAS Inhibitors Market Barriers

17. KRAS Inhibitors Appendix

18. KRAS Inhibitors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=kras-inhibitors-market-poised-for-significant-growth-from-2024-to-2034-reports-delveinsight-novartis-verastem-oncology-boehringer-ingelheim-roche-eli-lilly-revolution-medicines]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.